Novavax

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novavax and other ETFs, options, and stocks.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. 

CEO
John C.s Jacobs
CEOJohn C.s Jacobs
Employees
952
Employees952
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1987
Founded1987
Employees
952
Employees952

NVAX Key Statistics

Market cap
961.85M
Market cap961.85M
Price-Earnings ratio
-4.52
Price-Earnings ratio-4.52
Dividend yield
Dividend yield
Average volume
3.97M
Average volume3.97M
High today
$6.23
High today$6.23
Low today
$5.70
Low today$5.70
Open price
$5.89
Open price$5.89
Volume
10.73M
Volume10.73M
52 Week high
$23.86
52 Week high$23.86
52 Week low
$3.81
52 Week low$3.81

NVAX News

TipRanks 12h
Novavax believes BLA ‘ready for approval,’ waiting on action from FDA

Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “Novavax can confirm that April 1, 2025, was the U.S. Food and Dru...

Benzinga 13h
FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine

In September 2024, the U.S. Food And Drug Administration (FDA) granted Emergency Use Authorization to Novavax Inc.'s NVAX COVID-19 Vaccine, Adjuvanted (2024-202...

FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine
Simply Wall St 13h
Novavax (NasdaqGS:NVAX) Sees 21% Weekly Drop As Leadership Changes Shake Market

recently experienced a significant decline of 21% over the past week, coinciding with leadership changes, including the retirement of longtime Chairman James Yo...

Novavax (NasdaqGS:NVAX) Sees 21% Weekly Drop As Leadership Changes Shake Market

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
28.6%
Sell
14.3%

More NVAX News

Seeking Alpha 14h
Novavax bid for full approval of COVID vaccine stymied by FDA - report

The U.S. FDA has missed a key deadline to decide whether to grant full approval to Novavax's (NASDAQ:NVAX) COVID-19 vaccine. The agency was apparently poised t...

Novavax bid for full approval of COVID vaccine stymied by FDA - report
TipRanks 14h
Novavax put volume heavy and directionally bearish

Bearish flow noted in Novavax (NVAX) with 6,544 puts trading, or 7x expected. Most active are 4/4 weekly 6 puts and 4/4 weekly 5 puts, with total volume in thos...

TipRanks 15h
Novavax falls 4% to $5.76 after WSJ report on unlikely approval

12:21 EDT Novavax (NVAX) falls 4% to $5.76 after WSJ report on unlikely approval Published first on TheFly – the ultimate source for real-time, market-moving b...

Simply Wall St 21h
The Market Doesn't Like What It Sees From Novavax, Inc.'s Revenues Yet As Shares Tumble 28%

Novavax, Inc. ( ) shareholders that were waiting for something to happen have been dealt a blow with a 28% share price drop in the last month. Looking at the bi...

The Market Doesn't Like What It Sees From Novavax, Inc.'s Revenues Yet As Shares Tumble 28%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.